ASTELLAS PHARMA A/S: Financial statements 2019
CVR: 10888638
Source: annual report 2019, Danish Business Authority
01/04/2018 – 31/03/2019
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2019. In 2019, the company reported revenue of EUR 182,590,000 and a net result of EUR 4,735,000 compared with EUR 2,562,000 the year before. That is an increase of 15.7% compared with the year before. The profit margin was 2.6%. Equity in the 2019 report amounted to EUR 56,236,000. The solvency ratio was 43.4%. The company had 116 employees in the financial year.
- Revenue
- EUR 182,590,000
- Gross Profit
- EUR 25,019,000
- Profit/Loss
- EUR 4,735,000
- Equity
- EUR 56,236,000
- Total Assets
- EUR 129,628,000
- Employees
- 116
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | 182.6M EUR | 25M EUR | 4.7M EUR | 56.2M EUR | 116 |
| 2018 | 157.8M EUR | 20.5M EUR | 2.6M EUR | 54.1M EUR | 115 |
| 2017 | 144.9M EUR | 17.9M EUR | 12.2M EUR | 51.5M EUR | 117 |
| 2016 | 156M EUR | - | 6.7M EUR | 45.4M EUR | 118 |
| 2015 | 121.9M EUR | 25.8M EUR | 5.3M EUR | 38.7M EUR | 116 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
As of April 1, 2019, Pia Terésa Lindkvist has joined the board of directors of ASTELLAS PHARMA A/S.
As of April 1, 2019, Jan Anders Martin Nordén has left the board of directors of ASTELLAS PHARMA A/S.
As of April 1, 2019, Pia Terésa Lindkvist is registered as adm. dir. of ASTELLAS PHARMA A/S.
As of April 1, 2019, Jan Anders Martin Nordén has stepped down as adm. dir. of ASTELLAS PHARMA A/S.
About ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.